Home   ->   news   ->   Press Releases

Press Releases

WuXi AppTec Receives Inaugural “Company of the Year” Award from BayHelix

SHANGHAI, Oct. 21, 2016 --WuXi AppTec, a leading pharmaceutical, biotechnology, and medical device technology platform company, today announced that it has received the inaugural “Company of the Year” Award from BayHelix at a ceremony during the 3rd BioCentury China Healthcare Summit in Shanghai, China. The award is part of BayHelix China Healthcare Awards series, celebrating outstanding individuals and companies for their achievement and contribution to the China healthcare ecosystem.

WuXi is recognized for its industry leadership, consistent achievements, and global impact. BayHelix also cited WuXi’s contributions to its partners, patients and society with a number of big strides, including platform capability enhancement to better enable its customers, innovative collaboration models to bring better medicines faster to China, and strategic initiatives to embrace the future of health.

“We thank BayHelix for recognizing WuXi’s role in developing China’s local healthcare ecosystem,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “We will continue to strengthen our capability and technology platform to enable our collaborative partners, and to fulfill WuXi’s dream that every drug can be made and every disease can be treated.”

BayHelix is an organization of leaders of Chinese heritage in the global life sciences and healthcare community. China Healthcare Awards is presented in five categories, R&D Achievement of Year, Deal of the Year, Commercial Achievement of the Year, Company of the Year, and Person of the Year.

About WuXi AppTec

WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 2,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.”  Please visit http://www.wuxiapptec.com

For specific information on WuXi’s advanced therapy manufacturing please visit www.us.wuxiapptec.com

For more information, please contact:

WuXi AppTec
Sunnie Sun

back to top